Tabalumab (Systemic Lupus Erythematosus and Lupus Nephritis)：市場予測と分析（～2022）...市場調査レポートについてご紹介

1 Table of Contents
1 Table of Contents 5
1.1 List of Tables 8
1.2 List of Figures 8
2 Introduction 9
2.1 Catalyst 9
2.2 Related Reports 10
3 Disease Overview 12
3.1 Etiology and Pathophysiology 12
3.1.1 Etiology 12
3.1.2 Pathophysiology 14
3.2 Prognosis 15
3.3 Quality of Life 15
3.4 Symptoms 16
4 Disease Management 17
4.1 Diagnosis Overview 17
4.1.1 SLE Diagnosis 17
4.1.2 LN Diagnosis 20
4.2 Treatment Overview 22
5 Competitive Assessment 26
5.1 Overview 26
5.2 Strategic Competitor Assessment 27
6 Opportunity and Unmet Need 28
6.1 Overview 28
6.2 Unmet Needs 29
6.2.1 Efficacious Treatments with Reduced Side Effects 29
6.2.2 Management of LN 31
6.2.3 Improvement in Patients’ Mortality 32
6.2.4 Management of Lupus Comorbidities 32
6.2.5 Sensitive and Reliable Biomarkers 33
6.2.6 Physicians’ Education and Public Awareness of SLE 34
6.2.7 Unmet Needs Gap Analysis 34
6.3 Opportunities 35
6.3.1 Efficacious and Safe Therapies 35
6.3.2 Therapies Targeting LN Patients 36
6.3.3 Treatments for Common Lupus Comorbidities 37
6.3.4 Discovery of Biomarkers 37
7 Pipeline Assessment 38
7.1 Overview 38
7.2 Promising Drugs in Clinical Development 39
8 Tabalumab 42
8.1 Overview 42
8.2 Efficacy 43
8.3 Safety 44
8.4 Dosing and Formulation 44
8.5 Potential Clinical Positioning 44
8.6 Potential Commercial Positioning 45
8.7 Pricing and Reimbursement 45
8.8 SWOT Analysis 46
8.9 Forecast 46
9 Appendix 49
9.1 Bibliography 49
9.2 Abbreviations 51
9.3 Methodology 53
9.4 Forecasting Methodology 53
9.4.1 Diagnosed SLE and LN Patients 53
9.4.2 Percent Drug-Treated Patients 54
9.4.3 General Pricing Assumptions 54
9.4.4 Generic Erosion 55
9.4.5 Pricing of Pipeline Agents 55
9.5 Physicians and Specialists Included in this Study 55
9.6 Primary Research – Prescriber Survey 57
9.7 About the Authors 58
9.7.1 Analysts 58
9.7.2 Global Head of Healthcare 59
9.8 About GlobalData 60
9.9 Disclaimer 60